Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.47 |
| ▸ | PLG | P00747 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
| ▸ | FPGS | Q05932 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6019226 | 0.88 | CXCR4 (0.51) | CXCR4HPGDHSD17B10MAPK14HDAC3 | |
| SCHEMBL27597836 | 0.85 | CXCR4 (0.49) | CXCR4CA2FOLH1HPGDHSD17B10 | |
| SCHEMBL27566287 | 0.85 | CXCR4 (0.53) | CXCR4FOLH1CHRM2MAPK14 | |
| SCHEMBL6018116 | 0.85 | CXCR4 (0.53) | CXCR4FOLH1CHRM2MAPK14 | |
| SCHEMBL6671573 | 0.84 | CXCR4 (0.51) | CXCR4FOLH1CHRM2FPGS | |
| SCHEMBL27568576 | 0.83 | CXCR4 (0.47) | CXCR4CA2FOLH1HPGDHSD17B10 | |
| SCHEMBL6667469 | 0.83 | CXCR4 (0.47) | CXCR4CA2FOLH1HPGDHSD17B10 | |
| Phenylhydrazine SCHEMBL6690774 | 0.83 | CXCR4 (0.50) | CXCR4FOLH1CHRM2MAPK14 | |
| SCHEMBL6670076 | 0.82 | CXCR4 (0.48) | CXCR4CA2FOLH1HPGDHSD17B10 | |
| SCHEMBL6018262 | 0.81 | CXCR4 (0.57) | CXCR4CA2FOLH1MAPK14FPGS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157818-A1 | Cxcr4-antagonistic drugs composed of nitrogen-containing compound | KUREHA CORPORATION (JP) | 2004-08-12 | — | — | US | disclosed |
| EP-1389460-A1 | CXCR4-ANTAGONISTIC DRUGS COMPRISING NITROGEN-CONTAINING COMPOUND | Kureha Chemical Industry Co., Ltd. (JP) | 2004-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157818-A1 | Cxcr4-antagonistic drugs composed of nitrogen-containing compound | CXCR4, CXCR1, CXCR2 | CXCR4 1/4885PLG 3674/4885CA2 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.